| Date Filed | Type | Description |
| 08/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/04/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
8-K
| Quarterly results |
| 06/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/24/2023 |
SD
| Form SD - Specialized disclosure report: |
| 05/05/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/29/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/23/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 1% stake in BIO-RAD LABORATORIES INC |
| 01/10/2023 |
8-K
| Investor presentation |
| 11/08/2022 |
8-K
| Regulation FD Disclosure Interactive Data |
| 10/28/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/27/2022 |
8-K
| Quarterly results |
| 07/29/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/28/2022 |
8-K
| Quarterly results |
| 05/25/2022 |
SD
| Form SD - Specialized disclosure report: |
| 05/18/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/20/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Amendment No. 2 to Credit Agreement, by and among Bio-Rad Laboratories, Inc., the lenders referred to therein, and JPMorgan Chase Bank, N.A., as a lender and as administrative agent",
"Amendment No. 2 to Credit Agreement, by and among Bio-Rad Laboratories, Inc., the lenders referred to therein, and JPMorgan Chase Bank, N.A., as a lender and as administrative agent" |
|
| 04/11/2022 |
SC 13D/A
| SCHWARTZ ALICE N reports a 89.7% stake in Bio-Rad Laboratories, Inc. |
| 03/30/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/28/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/02/2022 |
8-K
| Quarterly results |
| 02/25/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
424B2
| Form 424B2 - Prospectus [Rule 424(b)(2)]: |
| 02/23/2022 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 02/23/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/15/2022 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
|